How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action
Health Science Reports · 2023-06 · 6 (6)
DOI: 10.1002/hsr2.1349 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Science Reports, online erschienen am 22.06.2023. Verfasst von Anne-Marie Baird und 9 weiteren Autor:innen. Beteiligte Einrichtung: Lung Cancer Europe (LuCE) Bern Switzerland. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Precision medicine (PM) is a form of personalized medicine that recognizes that individuals with the same condition may have different underlying factors and uses molecular information to provide tailored treatments. This approach can improve treatment outcomes and transform lives through favorable risk/benefit ratios, avoidance of ineffective interventions, and possible cost savings, as evidenced in the field of lung cancer and other oncology/therapeutic settings, including cardiac disease, diabetes, and rare diseases. However, the potential benefits of PM have yet to be fully realized.
Discussion
There are many barriers to the implementation of PM in clinical practice, including fragmentation of the PM landscape, siloed approaches to address shared challenges, unwarranted variation in availability and access to PM, lack of standardization, and limited understanding of patients' experience and needs throughout the PM pathway. We believe that a diverse, intersectoral multistakeholder collaboration, with three main pillars of activity: generation of data to demonstrate the benefit of PM, education to support informed decision‐making, and addressing barriers across the patient pathway, is necessary to reach the shared goal of making PM an accessible and sustainable reality. Besides healthcare providers, researchers, policymakers/regulators/payers, and industry representatives, patients in particular must be equal partners and should be central to the PM approach―from early research through to clinical trials and approval of new treatments―to ensure it represents their entire experience and identifies barriers, solutions, and opportunities at the point of delivery.
Conclusion
We propose a practical and iterative roadmap to advance PM and call for all stakeholders across the healthcare system to employ a collaborative, cocreated, patient‐centered methodology to close gaps and fully realize the potential of PM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lung Cancer Europe (LuCE) Bern Switzerland.
- From Testing to Targeted Treatments (FT3) Program Team, The Synergist Brussels Belgium.
- Comprehensive Cancer Center Munich and Department of Medicine III University Hospital, LMU Munich Munich Germany.
- Roche Basel Switzerland.
- Institut de Recerca Sant Joan de Déu Barcelona Spain.
- Innovation and Research Department, Hospital Sant Joan de Déu Pg Barcelona Spain.
ORCID-Profile: Helena Harnik
Zitieren
APA
Baird, A. M., Westphalen, C. B., Blum, S., Nafria, B., Knott, T., Sargeant, I., Harnik, H., Brooke, N., Wicki, N., & Wong-Rieger, D. (2023). How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action. Health Science Reports, 6(6). https://doi.org/10.1002/hsr2.1349
Vancouver
Baird AM, Westphalen CB, Blum S, Nafria B, Knott T, Sargeant I, et al. How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action. Health Science Reports. 2023;6(6). doi:10.1002/hsr2.1349
BibTeX
@article{Baird2023,
author = {Baird, Anne-Marie and Westphalen, C Benedikt and Blum, Sandra and Nafria, Begonya and Knott, Tanya and Sargeant, Ify and Harnik, Helena and Brooke, Nicholas and Wicki, Nicole and Wong-Rieger, Durhane},
title = {How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action},
journal = {Health Science Reports},
year = {2023},
volume = {6},
number = {6},
doi = {10.1002/hsr2.1349}
}
EUVIMED